3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
10
Gastrointestinal
9
Genitourinary
3
Tumor-Agnostic
2
Other solid neoplasm
2
Lymphoid
2
Head & Neck
2
Plasma cell
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Solid Tumors
1
PD-L1-selected Solid Tumors
1
Interventions
Injections
98
pembrolizumab
90
Carboplatin
57
Paclitaxel
54
Cisplatin
52
Nivolumab
44
Docetaxel
43
Pemetrexed
42
Gemcitabine
37
atezolizumab
32
tislelizumab
29
Bevacizumab
29
toripalimab
23
Fluorouracil
23
Capecitabine
23
Irinotecan
22
Oxaliplatin
20
durvalumab
19
Ipilimumab
18
Leucovorin
17
Cetuximab
17
Rifampin
14
Itraconazole
14
olaparib
13
spartalizumab
12
Midazolam
12
Cyclophosphamide
12
trifluridine tipiracil drug combination
11
sintilimab
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Tiragolumab
×
Other solid neoplasm
×
Clear all
NCT05661578
2026-02-09
SKYSCRAPER-11
Hoffmann-La Roche
Phase 2
Completed
64 enrolled
NCT06331598
2024-12-24
IMperator
Hoffmann-La Roche
Phase 2
Withdrawn